Red Day Pharmaceuticals entered with 800 million injections, and the original research Roche share only 10%

Medical Network May 15 hearing May 14, red medicine announcement that recently received ibandronate injection drug registration approval document issued by the State Food and Drug AdministrationMeters within the network data show that in 2019 China sales of public medical institutions terminal ibandronate of more than 800 million yuan, the earlier ibandronate injection approved domestic enterprises reached sevenTable 1: a granted a source information: Companyreported, ibandronic acid is the third-generation bisphosphonic acid salts drugs It was first launched by the injection Swiss pharmaceutical company Roche developed in 1996 in Germany, mainly for the treatment of postmenopausal osteoporosis, prevention of bone metastases in breast cancer patients with bone-related events (including pathologic fractures, radiation or surgery needed bone complications), malignanttreatment with or without hypercalcemia caused by bone metastasesCompared with other bisphosphonate drugs, the product has high efficiency, low toxicity, ease of use, broad indications, etc., particularly nephrotoxicity in bisphosphonates minimum, the maximum of the renal safety, clinical have a stronger advantage on the applicationFigure 1: Sales of public medical institutions terminal Chinese ibandronic acid (unit: million)Source: network terminal competition Chinese public medical institutions
Figure 2: 2019 Chinese public medical institutions terminal ibandronate corporate structuresource: network terminal competition Chinese public medical institutions within meterswithinmeters network data show that in 2019 generic name TOP20 publicChinese cities, county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal in the treatment of bone, ibandronate ranked fifth, sales the amount of over 800 million yuan, Hebei Medical University, biological, Chengdu East Court biopharmaceutical market share of over 30%, only 10.49% of the original research pharmaceutical companies Roche's market shareCurrently, reporting ibandronate injection has a consistency in evaluation of Chengdu Court East Qilu Pharmaceutical biotechnology and related reception number in the review and approval of allSource: Company, meters network database